背景与目的:欧、美国家的乳腺癌患者以中老年居多,中位年龄约57岁左右;改良根治术已取代传统根治术而被称为标准根治术,早期患者则行保乳手术;肿瘤的分期(尤其淋巴结状况)明显影响预后;辅助治疗能提高疗效。在国内,有关乳腺癌临床研究的大宗报道甚少。本研究分析我院可手术乳腺癌6263例的临床特点、手术方式与治疗效果,分析影响预后的因素和辅助治疗的作用等情况,以期提高乳腺癌的诊治水平。方法:将我院1964年6月～2003年6月收治的6263例可手术乳腺癌的临床资料输入计算机并分析可手术乳腺癌患者年龄的分布和临床特点。用SPSS10.0统计软件,分析手术术式与治疗效果以及影响预后的因素和辅助治疗的作用等情况。结果:6263例可手术乳腺癌中,女性占98.8%。按每5岁年龄段计算,45～49岁最多(25.2%)。按每10岁年龄段计算,40～49岁最多(41.0%)。临床表现以乳腺肿块为主(96.2%)。全组总5年和10年生存率分别为75.2%和40.4%,0～Ⅰ期、Ⅱ期和Ⅲ期的5年生存率分别为96.8%、73.7%和46.4%,10生存率则分别为78.7%、64.6%和33.5%。腋窝淋巴结阴性和阳性的5年生存率分别为80.3%和55.6%,而10年生存率分别为59.2%和31.9%。20世纪80年代后作传统根治术和改良根治术后各期的5年和10年生存率相比较,均无统计学意义(P>0.05)。早期 Background and Objective: Breast cancer patients in Europe and the United States are mostly middle-aged and elderly patients, with a median age of about 57 years. Modified radical mastectomy has replaced traditional radical mastectomy and is considered as standard radical mastectomy. Early patients underwent breast conserving surgery. (Especially lymph node status) significantly affect the prognosis; adjuvant therapy can improve the efficacy. In China, few reports have been reported on the clinical research of breast cancer. This study analyzed 6263 cases of operable breast cancer hospital in our hospital clinical features, surgical methods and treatment effects, analysis of prognostic factors and the role of adjuvant therapy in order to improve the diagnosis and treatment of breast cancer. Methods: The clinical data of 6263 cases of operable breast cancer admitted from June 1964 to June 2003 in our hospital were entered into the computer and the age distribution and clinical features of the operable breast cancer were analyzed. SPSS10.0 statistical software was used to analyze the surgical procedures and treatment effects as well as the factors that affect the prognosis and the role of adjuvant therapy. Results: 6263 cases of operable breast cancer, women accounted for 98.8%. According to every five-year age group, 45 to 49 years old (25.2%). According to the age of 10 years of age, 40 to 49 years old (41.0%). The main clinical manifestations of breast lumps (96.2%). The overall 5-year and 10-year survival rates were 75.2% and 40.4% respectively. The 5-year survival rates were 0% in stage 0, stage Ⅰ, stage Ⅲ, and stage Ⅲ were 96.8%, 73.7% and 46.4% 78.7%, 64.6% and 33.5%. The 5-year survival rates of negative and positive axillary lymph nodes were 80.3% and 55.6%, respectively, while the 10-year survival rates were 59.2% and 31.9%, respectively. There was no significant difference in 5-year and 10-year survival rates between the two groups after conventional radical mastectomy and modified radical mastectomy after the 1980s (P> 0.05). Early